First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes

AIM: To investigate the performance of the Eversense XL implantable continuous glucose monitoring (CGM) system through 180 days in a primarily adolescent population with type 1 diabetes (T1D). MATERIALS AND METHODS: This prospective, single‐centre, single‐arm, 180‐day study evaluated the effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Aronson, Ronnie, Abitbol, Alexander, Tweden, Katherine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618327/
https://www.ncbi.nlm.nih.gov/pubmed/30938036
http://dx.doi.org/10.1111/dom.13726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618327/
https://www.ncbi.nlm.nih.gov/pubmed/30938036
http://dx.doi.org/10.1111/dom.13726

Ejemplares similares